Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

Published:2008-12 Issue:6 Volume:2 Page:426-435
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Bays Harold E.,Jones Peter H.,Mohiuddin Syed M.,Kelly Maureen T.,Sun Hsiaoming,Setze Carolyn M.,Buttler Susan M.,Sleep Darryl J.,Stolzenbach James C.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference18 articles.

1. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia;Ellen;Am J Cardiol,1998

2. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia;Athyros;Diabetes Care,2002

3. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome;Vega;Am J Cardiol,2003

4. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia;Durrington;Diabetes Res Clin Pract,2004

5. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial);Grundy;Am J Cardiol,2005

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological management of diabetic dyslipidemia;Expert Review of Clinical Pharmacology;2016-12-02

2. Fibrates for primary prevention of cardiovascular disease events;Cochrane Database of Systematic Reviews;2016-11-16

3. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease;Expert Opinion on Investigational Drugs;2015-01-21

4. Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence;Research and Reports in Endocrine Disorders;2014-12

5. Rosuvastatin for lowering lipids;Cochrane Database of Systematic Reviews;2014-11-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3